Cargando…

Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study

BACKGROUND: Different medical therapies are employed in acute lung injury (ALI) but there is still a debate about the efficacy of these drugs. Among these therapies steroids are clinically applied and bosentan is experimentally studied. The aim of this study was to evaluate the efficacy of these two...

Descripción completa

Detalles Bibliográficos
Autores principales: Araz, Omer, Demirci, Elif, Yilmazel Ucar, Elif, Calik, Muhammet, Pulur, Didem, Karaman, Adem, Yayla, Muhammed, Altun, Eren, Halici, Zekai, Akgun, Metin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891975/
https://www.ncbi.nlm.nih.gov/pubmed/24342001
http://dx.doi.org/10.1186/2049-6958-8-74
_version_ 1782299436681003008
author Araz, Omer
Demirci, Elif
Yilmazel Ucar, Elif
Calik, Muhammet
Pulur, Didem
Karaman, Adem
Yayla, Muhammed
Altun, Eren
Halici, Zekai
Akgun, Metin
author_facet Araz, Omer
Demirci, Elif
Yilmazel Ucar, Elif
Calik, Muhammet
Pulur, Didem
Karaman, Adem
Yayla, Muhammed
Altun, Eren
Halici, Zekai
Akgun, Metin
author_sort Araz, Omer
collection PubMed
description BACKGROUND: Different medical therapies are employed in acute lung injury (ALI) but there is still a debate about the efficacy of these drugs. Among these therapies steroids are clinically applied and bosentan is experimentally studied. The aim of this study was to evaluate the efficacy of these two drugs to treat inflammation in ALI by histopathological comparison. METHODS: The five experimental groups (n = 5 per group) were: saline control (Group I); lipopolysaccharide (LPS) + saline (Group II); LPS + dexamethasone (Group III); LPS + 50 mg/kg bosentan (Group IV); and LPS + 100 mg/kg bosentan (Group V). Bosentan was administered orally one hour before and 12 hours after LPS treatment. Dexamethasone was administered intraperitoneally in three doses of 1 mg/kg; one dose was co-administered with LPS and the other two doses were given respectively 30 minutes before and after LPS treatment. Vasodilation-congestion, hemorrhage, polymorphonuclear leukocyte (PMN) infiltration, mononuclear leukocyte (MNL) infiltration, alveolar wall thickening, alveolar destruction/emphysematous appearance, and focal organization were the parameters used as criteria for evaluating inflammation and efficacy of treatment. RESULTS: Compared to the LPS-only group (Group II), dexamethasone treatment (Group III) resulted in significant improvements in vasodilation-congestion, hemorrhage, PMN and MNL infiltration, alveolar wall thickening and emphysematous areas. Treatment with 50 mg/kg dose of bosentan (Group IV) also resulted in significant improvements in hemorrhage, PMN and MNL infiltration, alveolar wall thickening and alveolar destruction. Reducing lung injury and reparative effects of 100 mg/kg bosentan were significant in all parameters. CONCLUSIONS: Bosentan is as effective as dexamethasone for treating lung injury in ALI. Bosentan at 100 mg/kg can be recommended as a first treatment choice based on its significant reducing lung injury and reparative effects.
format Online
Article
Text
id pubmed-3891975
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38919752014-01-15 Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study Araz, Omer Demirci, Elif Yilmazel Ucar, Elif Calik, Muhammet Pulur, Didem Karaman, Adem Yayla, Muhammed Altun, Eren Halici, Zekai Akgun, Metin Multidiscip Respir Med Original Research Article BACKGROUND: Different medical therapies are employed in acute lung injury (ALI) but there is still a debate about the efficacy of these drugs. Among these therapies steroids are clinically applied and bosentan is experimentally studied. The aim of this study was to evaluate the efficacy of these two drugs to treat inflammation in ALI by histopathological comparison. METHODS: The five experimental groups (n = 5 per group) were: saline control (Group I); lipopolysaccharide (LPS) + saline (Group II); LPS + dexamethasone (Group III); LPS + 50 mg/kg bosentan (Group IV); and LPS + 100 mg/kg bosentan (Group V). Bosentan was administered orally one hour before and 12 hours after LPS treatment. Dexamethasone was administered intraperitoneally in three doses of 1 mg/kg; one dose was co-administered with LPS and the other two doses were given respectively 30 minutes before and after LPS treatment. Vasodilation-congestion, hemorrhage, polymorphonuclear leukocyte (PMN) infiltration, mononuclear leukocyte (MNL) infiltration, alveolar wall thickening, alveolar destruction/emphysematous appearance, and focal organization were the parameters used as criteria for evaluating inflammation and efficacy of treatment. RESULTS: Compared to the LPS-only group (Group II), dexamethasone treatment (Group III) resulted in significant improvements in vasodilation-congestion, hemorrhage, PMN and MNL infiltration, alveolar wall thickening and emphysematous areas. Treatment with 50 mg/kg dose of bosentan (Group IV) also resulted in significant improvements in hemorrhage, PMN and MNL infiltration, alveolar wall thickening and alveolar destruction. Reducing lung injury and reparative effects of 100 mg/kg bosentan were significant in all parameters. CONCLUSIONS: Bosentan is as effective as dexamethasone for treating lung injury in ALI. Bosentan at 100 mg/kg can be recommended as a first treatment choice based on its significant reducing lung injury and reparative effects. BioMed Central 2013-12-17 /pmc/articles/PMC3891975/ /pubmed/24342001 http://dx.doi.org/10.1186/2049-6958-8-74 Text en Copyright © 2013 Araz et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Research Article
Araz, Omer
Demirci, Elif
Yilmazel Ucar, Elif
Calik, Muhammet
Pulur, Didem
Karaman, Adem
Yayla, Muhammed
Altun, Eren
Halici, Zekai
Akgun, Metin
Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study
title Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study
title_full Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study
title_fullStr Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study
title_full_unstemmed Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study
title_short Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study
title_sort comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891975/
https://www.ncbi.nlm.nih.gov/pubmed/24342001
http://dx.doi.org/10.1186/2049-6958-8-74
work_keys_str_mv AT arazomer comparisonofreducingeffectonlunginjuryofdexamethasoneandbosentaninacutelunginjuryanexperimentalstudy
AT demircielif comparisonofreducingeffectonlunginjuryofdexamethasoneandbosentaninacutelunginjuryanexperimentalstudy
AT yilmazelucarelif comparisonofreducingeffectonlunginjuryofdexamethasoneandbosentaninacutelunginjuryanexperimentalstudy
AT calikmuhammet comparisonofreducingeffectonlunginjuryofdexamethasoneandbosentaninacutelunginjuryanexperimentalstudy
AT pulurdidem comparisonofreducingeffectonlunginjuryofdexamethasoneandbosentaninacutelunginjuryanexperimentalstudy
AT karamanadem comparisonofreducingeffectonlunginjuryofdexamethasoneandbosentaninacutelunginjuryanexperimentalstudy
AT yaylamuhammed comparisonofreducingeffectonlunginjuryofdexamethasoneandbosentaninacutelunginjuryanexperimentalstudy
AT altuneren comparisonofreducingeffectonlunginjuryofdexamethasoneandbosentaninacutelunginjuryanexperimentalstudy
AT halicizekai comparisonofreducingeffectonlunginjuryofdexamethasoneandbosentaninacutelunginjuryanexperimentalstudy
AT akgunmetin comparisonofreducingeffectonlunginjuryofdexamethasoneandbosentaninacutelunginjuryanexperimentalstudy